Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.33)
# 992
Out of 5,154 analysts
168
Total ratings
46.39%
Success rate
2.97%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $8.36 | +211.00% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $63.54 | -0.85% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $11.10 | +1,224.32% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $87.01 | -5.76% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $13.20 | -24.24% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $25.86 | +8.28% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.96 | +940.37% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $32.72 | +217.85% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $4.45 | +394.38% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.74 | +704.60% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $144.28 | -35.54% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $38.83 | +75.12% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $20.35 | +420.88% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $6.18 | +142.91% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $14.68 | +281.47% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $13.34 | +327.29% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $7.01 | +213.84% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.99 | +754.27% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $4.38 | +699.09% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $82.35 | -53.86% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.50 | +906.85% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $56.03 | -32.18% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $7.14 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.16 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.67 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $11.99 | +2,151.88% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $182.77 | - | 2 | Apr 23, 2020 |
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $8.36
Upside: +211.00%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $63.54
Upside: -0.85%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $11.10
Upside: +1,224.32%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $87.01
Upside: -5.76%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $13.20
Upside: -24.24%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $25.86
Upside: +8.28%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.96
Upside: +940.37%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $32.72
Upside: +217.85%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $4.45
Upside: +394.38%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.74
Upside: +704.60%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $144.28
Upside: -35.54%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $38.83
Upside: +75.12%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $20.35
Upside: +420.88%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $6.18
Upside: +142.91%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $14.68
Upside: +281.47%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $13.34
Upside: +327.29%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $7.01
Upside: +213.84%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.99
Upside: +754.27%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $4.38
Upside: +699.09%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $82.35
Upside: -53.86%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.50
Upside: +906.85%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $56.03
Upside: -32.18%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $7.14
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.16
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.67
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $11.99
Upside: +2,151.88%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $182.77
Upside: -